From Discovery to Clinical Testing: HistologiX and Antibody Analytics Forge Ground-breaking Alliance
HistologiX has recently announced that they have entered a strategic partnership with Antibody Analytics, a leading provider of immunology research services and characterisation of antibody-targeted therapeutics. This partnership allows them to expand their offerings to include a range of cutting-edge antibody testing services, ensuring that their customers have access to the most advanced technology and expertise in the industry.
Antibody Analytics has a long history of providing high-quality, reliable cell-based assay solutions to clients across a wide range of industries. Their cutting-edge technology and expertise make them an ideal partner for HistologiX. The alliance aims to bring significant benefits to their customers, as both companies share a strong commitment to providing high-quality research services.
“We are delighted to be partnering with Antibody Analytics, their commitment to providing high-quality research services aligns perfectly with our own values, and we are excited to work together to offer even more advanced solutions to our customers and strengthen our offerings.”
Barbara McManus, Managing Director of HistologiX
“HistologiX is one of the leaders in histology, image analysis and digital pathology and through this collaboration, Antibody Analytics is now able to provide more comprehensive support to our customers with target discovery, pre-clinical and clinical histology analysis needs. Antibody Analytics offers comprehensive in vitro immunopharmacology and immunotoxicology services from the very earliest stages of the drug discovery process, starting from target discovery, through lead identification and selection to product characterization.
Our partnership with HistologiX will expand this to immunohistochemical efficacy & toxicity biomarker assays (pre-clinical and clinical) and tissue cross reactivity (TCR) assessments. This is an exciting opportunity for both companies and allows expansion of our capabilities from early discovery to clinical testing for targeted biologics.”
Dr. Agapitos Patakas, Antibody Analytics’ Chief Scientific Officer
By joining forces, HistologiX and Antibody Analytics are set to ensure that customers have access to the most advanced solutions in the ever-evolving biotech industry.
Click HERE to access their announcement
